Drug-repositioning screens identify Triamterene as a selective drug for the treatment of DNA Mismatch Repair deficient cells.

Guillotin, D, Austin, P, Begum, R et al. (6 more authors) (2017) Drug-repositioning screens identify Triamterene as a selective drug for the treatment of DNA Mismatch Repair deficient cells. Clinical Cancer Research, 23 (11). pp. 2869-2879. ISSN 1078-0432

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016, American Association for Cancer Research. This is an author produced version of a paper published in Clinical Cancer Research. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 21 November 2016
  • Published (online): 2 December 2016
  • Published: 1 June 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 19 Dec 2016 16:10
Last Modified: 02 Dec 2017 01:38
Published Version: https://doi.org/10.1158/1078-0432.CCR-16-1216
Status: Published
Publisher: American Association for Cancer Research
Identification Number: https://doi.org/10.1158/1078-0432.CCR-16-1216
Related URLs:

Share / Export

Statistics